Executive Series Breakfast: Korea Life Science Companies Entering and Expanding in U.S. Market
Navigating the U.S. Competitive Reimbursement, Regulatory, Clinical, and Commercial Landscape: A Primer for Korean Life Science Companies
View in Korean ÌïúÍµ≠Ïñ¥Î°úÎ≥¥Í∏∞
Relations between the United States and Korea are rapidly strengthening because of the U.S.-Korea Free Trade Agreement (KORUS FTA), which entered into force one year ago. Korean Life Sciences Companies with a U.S. presence, or who are seeking to expand into the U.S., can enhance their competitiveness with a solid understanding of the evolving U.S. healthcare environment. The implementation of the Affordable Care Act and other regulatory and reimbursement developments have created new complexities in accessing the market. These include the increasing importance of quantifying clinical value; identifying the specific patient group(s) most likely to benefit from expensive therapies to qualify for treatment; and the need for workable strategies to obtain governmental and commercial reimbursement in this evolving environment. Success in the US market, however, will require a keen understanding of the clinical, regulatory, reimbursement, policy, pricing, coverage, commercial, and legal environment and requirements.
Join Moderators Tom Barker, Partner/Co-Chair of the Healthcare Practice, Foley Hoag LLP and Paula Ness Speers, Partner & Managing Director, Health Advances for an overview of U.S. competitive reimbursement and clinical strategy and to discuss their applicability to fueling emerging Korean Life Science Companies operating, partnering, or planning to expand in the United States.
Partner/Co-Chair of the Healthcare Practice, Foley Hoag LLP
Paula Ness Speers
Partner & Managing Director, Health Advances
Korea Life Science Industry Executive Series Breakfast and Networking Event @ BIO 2013
Wednesday, April 24, 2013
Hyatt Regency McCormick Place
RSVP by April 12
|Attire:||Business Attire Suggested|